Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Total Liabilities (2018 - 2025)

10x Genomics (TXG) has disclosed Total Liabilities for 8 consecutive years, with $245.0 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 17.52% to $245.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $245.0 million through Dec 2025, up 17.52% year-over-year, with the annual reading at $245.0 million for FY2025, 17.52% up from the prior year.
  • Total Liabilities hit $245.0 million in Q4 2025 for 10x Genomics, up from $242.2 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $245.0 million in Q4 2025 to a low of $190.4 million in Q3 2021.
  • Historically, Total Liabilities has averaged $210.2 million across 5 years, with a median of $206.2 million in 2024.
  • Biggest five-year swings in Total Liabilities: decreased 12.47% in 2021 and later grew 17.52% in 2025.
  • Year by year, Total Liabilities stood at $201.3 million in 2021, then grew by 10.92% to $223.2 million in 2022, then grew by 0.39% to $224.1 million in 2023, then fell by 6.96% to $208.5 million in 2024, then rose by 17.52% to $245.0 million in 2025.
  • Business Quant data shows Total Liabilities for TXG at $245.0 million in Q4 2025, $242.2 million in Q3 2025, and $206.7 million in Q2 2025.